Children who are HIV-exposed but uninfected (CHEU) have more infectious morbidity and mortality than children who are HIV-unexposed (CHU), particularly in early life. We hypothesised that CHEU may have immunological abnormalities in infancy despite not living with HIV.
T-cell and monocyte immunophenotyping of fixed buffy-coat cells was undertaken by flow cytometry in a subgroup of participants of the SHINE trial in rural Zimbabwe. Proportions of T-cell and monocyte subsets, defined by surface and intracellular markers, were compared between CHEU and CHU aged 1-month using fractional regression, adjusted for infant sex and exact age in days.
146 CHEU and 142 CHU were included. 140/146 (96%) of CHEU were also antenatally-exposed to antiretroviral therapy (ART). Compared to CHU, a lower proportion of CD8+ T-cells in CHEU were naïve cells (CD45RA+/CD27+; mean 82.7% (standard deviation [SD] 22.0) vs. 90.0% (12.4), adjusted difference -7.4% [95%CI -13.0, -1.9], P=0.008), and higher proportions were central memory (CD45RA-/CD27+; +3.6% [0.6, 6.6], P=0.020) or effector memory (CD45RA-/CD27-; +2.1% [0.7, 3.5], P=0.003) cells. Higher proportions of CD8+ T-cells were proliferating (Ki67+; 15.2% (19.4) vs. 9.3% (11.5), +6.1% [1.7, 10.5], P=0.006) or co-expressing CD38 and HLA-DR activation makers (12.1% (16.5) vs. 6.4% (8.8), +4.3% [1.4, 7.2], P=0.003). There were no differences in CD4+ T-cell subsets. Compared to CHU, CHEU had higher concentrations of soluble CD14 (mean 1.10×106 (SD 0.4) pg/mL vs. 0.85×106 (0.4) pg/mL, adjusted difference 0.25×106 [95%CI 0.15×106, 0.35×106], P<0.001) and lower proportions of classical monocytes (CD14+/CD16-; 57.5% (13.7) vs. 61.7% (15.5); -4.5% [-8.7, -0.2]; P=0.04). Monocyte population differences between CHEU and CHU were stronger in males compared to females, mostly driven by an expansion in non-classical (+6.2% [95%CI 0.0, 12.4]; P=0.05) rather than intermediate (-0.3% [95%CI -3.0, 0.2], P=0.84), monocytes.
Despite high maternal ART coverage, CHEU have a distinct cellular immune phenotype relative to CHU. Future work should explore associations between infant immunity and clinical outcomes. Strategies additional to antenatal ART may be required to improve outcomes amongst HIV-exposed children.